AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00580905
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion.
Trial: NCT00529841
Drug: Hydrocortisone sodium acetate
RxNorm normalized name: Hydrocortisone Sodium Phosphate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of medication via insulin pump
Trial: NCT02158039
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
Trial: NCT01744730
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
Trial: NCT01527916
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT01527916
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose, middle dose, high dose
Trial: NCT02534610
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
Trial: NCT02534610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
Trial: NCT00732121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00233025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00612313
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
Trial: NCT02556710
Drug: 4 mL injection of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL Injection of Placebo
Trial: NCT01709318
Drug: Estradiol (E2)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily release of 300 μg
Trial: NCT01903694
Drug: Sorafenib + Pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02229097
Drug: Normal bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period
Trial: NCT01323569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 placebo sprays and 4 placebo capsules
Trial: NCT01728155
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05905185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg of Placebo
Trial: NCT01010581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01010581
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral administration
Trial: NCT01010581
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00809289
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily administration of placebo for 9 days. Placebo will be administered double blind
Trial: NCT03226067
Drug: GKT137831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
Trial: NCT03226067
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules.
Trial: NCT00111644
Drug: beta-lactam
RxNorm normalized name: Beta-lactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750mg iv q 23h for 3-14 days
Trial: NCT00111644
Drug: beta-lactam
RxNorm normalized name: Beta-lactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500mg iv q 12h for 3-14 days
Trial: NCT01662869
Drug: 5-Fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Trial: NCT01662869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
Trial: NCT01914432
Drug: YH16410
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01914432
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01914432
Drug: YH16410 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01914432
Drug: Rosuvastatin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00907894
Drug: LDT600 (Telbivudine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDT600 (Telbivudine)
Trial: NCT00843791
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with placebo for 3 months
Trial: NCT01324024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
Trial: NCT01531959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to blinded placebo control
Trial: NCT02057757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days.
Trial: NCT02442921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo
Trial: NCT00650533
Drug: Amaryl® Tablets 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg, single dose fed
Trial: NCT00621439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo.
Trial: NCT00600964
Drug: GX15-070MS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 60-minute or 3-hour IV infusion every 2-3 weeks.
Trial: NCT00600964
Drug: GX15-070MS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GX15-070MS at various doses and schedules
Trial: NCT03395535
Drug: Primary Medical Treatment Pathway
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary.
Trial: NCT02461589
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously ( s.c., under the skin) once daily.
Trial: NCT01646034
Drug: carboplatin, thiotepa, and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
Trial: NCT02233231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: similar tabl
Trial: NCT03036514
Drug: Patient-controlled intravenous analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
Trial: NCT01336465
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating subcutaneous injection
Trial: NCT01048138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg IV(in the vein)every 6 hours for 10 days
Trial: NCT03880578
Drug: Levothyroxine Sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: thyroid hormone replacement
Trial: NCT02422381
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug.
Trial: NCT03957174
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose as control condition
Trial: NCT01025700
Drug: Cesemat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg capsule per day for 21 days
Trial: NCT02928692
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02928692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01851005
Drug: Propofol and Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control effect site concentration for maintain BIS 40\~45 and changes of vital signs within 20%.
Trial: NCT01851005
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use as placebo
Trial: NCT00322062
Drug: macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate
RxNorm normalized name: ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2L gut lavage solution
Trial: NCT00574860
Drug: EN3285
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rinse
Trial: NCT00574860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rinse
Trial: NCT02640729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, oral, matching tablets
Trial: NCT03006406
Drug: Long term GnRH-a (3.75mg)
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
Trial: NCT01696032
Drug: Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
Trial: NCT01233297
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/kg peroral for 3 consecutive days
Trial: NCT01975389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
Trial: NCT01312961
Drug: Placebo (for Dupilumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, one subcutaneous injection.
Trial: NCT03435094
Drug: Binosto 70Mg Effervescent Tablet
RxNorm normalized name: Binosto 70mg Effervescent Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.
Trial: NCT00999349
Drug: Silymarin (LEGALON)
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
Trial: NCT00999349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002495
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 on days 1 and 15
Trial: NCT01164046
Drug: low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
Trial: NCT01164046
Drug: vitamin K antagonists
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target INR between 2-3. Any type allowed, if approved for use in that country.
Trial: NCT02570321
Drug: Anti Fungal Drug
RxNorm normalized name: miconazole nitrate Topical Cream [Anti-Fungal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Amphotericin B vs Topical Natamycin
Trial: NCT01632579
Drug: LY3023703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01632579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01632579
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03481946
Drug: BAY1093884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg given intravenously
Trial: NCT03481946
Drug: BAY1093884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg given intravenously
Trial: NCT03156231
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Trial: NCT03966235
Drug: Melatonin 3 mg
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin was taken daily for 6 months.
Trial: NCT03966235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet was taken daily for 6 months.
Trial: NCT02120924
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
Trial: NCT03772405
Drug: Nascum Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal application of nascum plus
Trial: NCT03857438
Drug: Ongoing treatment for bipolar mania
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed by the following doctor during hospitalization and after discharge
Trial: NCT01688336
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~* Oxaliplatin (85 mg/m2)~* Leucovorin (400mg/ m2)~* Irinotecan (180 mg/m2)~* 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours
Trial: NCT03208972
Drug: hp-FSH
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00268528
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00268528
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01690403
Drug: EFZ EMT TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Trial: NCT01513317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a 1-hour intravenous infusion every 4 weeks
Trial: NCT01513317
Drug: Best supportive care (BSC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care according to local standards and guidelines
Trial: NCT02338843
Drug: LJPC-501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm
Trial: NCT02338843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBO
Trial: NCT01825551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01032694
Drug: Azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin SR, 2.0 g PO x 1 dose for treatment period
Trial: NCT01032694
Drug: Amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxiclav 1000 x twice daily, 10 days duration
Trial: NCT01027910
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously on Day 4 of each 3 week cycle
Trial: NCT02805842
Drug: Advagraf QD
RxNorm normalized name: Astagraf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of Advagraf QD
Trial: NCT03063229
Drug: Hepatic Mitochondrial Oxidation breath test
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
Trial: NCT02855502
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02855502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01657201
Drug: SYP-1018 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYP-1018 200mg, Intravenous administration
Trial: NCT02497326
Drug: Topical Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval
Trial: NCT01040871
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Trial: NCT01040871
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Trial: NCT01256775
Drug: NCX4016 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX4016 placebo b.i.d. for 6 months
Trial: NCT01984723
Drug: Experimental: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01465802
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline or Doxycycline placebo BID for 4 weeks
Trial: NCT03037151
Drug: Grazaoprevir/Elbasavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment naive
Trial: NCT03037151
Drug: Grazaoprevir/Elbasavir/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment experienced
Trial: NCT02773797
Drug: IN-DEX 1.5 mcg/kg, intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02773797
Drug: Placebo - Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02252081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill(s) orally per day for 16 weeks
Trial: NCT02595684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcined magnesia capsules: one per day, at night, during 28 days.
Trial: NCT03503968
Drug: MDG1011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRAME-T-Cell Receptor Gene Modified Autologous T Cells
Trial: NCT03771729
Drug: LCZ 696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 200mg twice daily